Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Cervical cancer remains a leading malignancy among women worldwide. Emerging evidence suggests that alterations in the cervical microbiota may influence its development and progression.
Objective: To compare the cervical microbiota composition and diversity between cervical cancer patients and healthy women using 16S rRNA gene sequencing.
Methods: Between January and June 2024, cervical tissue samples were collected from 40 cervical cancer patients and 40 healthy women. Microbial DNA was extracted and the V3-V4 region of the 16S rRNA gene was sequenced using the Illumina Novaseq 6000 platform. QIIME2 and R software were used for microbial classification and diversity analysis. LEfSe was applied to identify differentially abundant taxa between groups.
Results: At the phylum level, dominated the control group (67.91%), while dropped to 31.03% in cervical cancer patients. (26.22% vs 14.37%) and (27.61% vs 0.72%) were significantly elevated in the cancer group. At the genus level, was predominant in controls (46.27%), while reduced in patients, and Rhodococcus and Klebsiella were notably enriched. Alpha diversity (Shannon index) exhibited no significant difference between groups, whereas richness indices (Chao1 and ACE) were significantly higher in the cancer group (p < 0.05). Beta diversity analysis revealed a clear distinction in community structure (t = 10.225, P = 0.001). LEfSe identified Rhodococcus (LDA = 5.24), Klebsiella (LDA = 5.17), and Ralstonia as significantly more abundant in the cancer group, while (LDA = 5.31) was characteristic of the control group.
Conclusion: Cervical cancer patients exhibited distinct cervical microbiota profiles, with reduced Firmicutes and elevated Actinobacteria and Proteobacteria. Increased levels of Rhodococcus and Klebsiella suggested a potential association between microbial dysbiosis and cervical cancer. These findings highlight the microbiome's relevance to tumor biology and support further investigation into its diagnostic and therapeutic potential.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067470 | PMC |
| http://dx.doi.org/10.2147/IJGM.S520936 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomized Controlled Trial of Impact of Mobile Health Technologies on Human Papillomavirus Vaccination Uptake in Mothers of Vaccine-Eligible Girls in Lagos, Nigeria (mHealth-HPVac).
JCO Glob Oncol
May 2025
Department of Obstetrics and Gynaecology, Stanford University School of Medicine, Stanford, CA.
Purpose: Expanding high-risk human papillomavirus (HPV) vaccine coverage in resource-constrained settings is critical to bridging the cervical cancer gap and achieving the global action plan for elimination. Mobile health (mHealth) technology via short message services (SMS) has the potential to improve HPV vaccination uptake. The mHealth-HPVac study evaluated the effectiveness of mHealth interventions in increasing HPV vaccine uptake among mothers of unvaccinated girls aged 9-14 years in Lagos, Nigeria.
View Article and Find Full Text PDFEstrogen therapy in patients with gynecologic cancer: a survey of gynecologists and oncologists in the United States.
Menopause
September 2025
Department of Gynecologic Oncology, Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY.
Objective: Endometrial cancer (EC) and epithelial ovarian cancer (EOC) affect women of all ages, and the incidence of endometrial cancer in premenopausal women is rising. Menopause can be detrimental to longevity and quality of life, but evidence suggests estrogen therapy (ET) is safe in these patients. The purpose of this study was to evaluate the practice patterns of gynecologists and gynecologic oncologists (GYO) in the United States in regards to prescription of ET to gynecologic cancer patients.
View Article and Find Full Text PDFBarriers and facilitators to implementing a single-visit, screen-and-treat approach with thermal ablation for cervical cancer prevention in Kenya.
PLOS Glob Public Health
September 2025
Department of Child, Family, and Population Health Nursing, School of Nursing, University of Washington, Seattle, Washington, United States of America.
Cervical cancer continues to be a major global threat to women's health, with approximately 660,000 women diagnosed annually, 94% of whom are in low- and middle-income countries (LMICs). The high disease burden in LMICs is partly due to suboptimal adoption and widespread implementation of effective preventive interventions. This study explored drivers of implementation success and failure for a future single-visit, screen, and treat approach with thermal ablation (SV-SAT + TA), referred to as TIBA in Kenya.
View Article and Find Full Text PDFTwo Cases of Primary Melanoma of the Uterine Cervix.
Am J Case Rep
September 2025
Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan.
BACKGROUND This study reports on 2 cases of cervical melanoma with similar presentations but at different stages, and the treatment strategy varied accordingly, and we review the literature on the characteristics, diagnosis, and management of cervical melanoma. CASE REPORT Case 1: A 69-year-old woman with abnormal vaginal bleeding was diagnosed with advanced cervical melanoma, staged as International Federation of Gynecology and Obstetrics (FIGO) Stage IVB, involving multiple metastases. Despite chemoradiotherapy and immunotherapy (nivolumab), the disease progressed rapidly, and the patient died 4 months after diagnosis.
View Article and Find Full Text PDFThe Future of Cervical Cancer Screening Is Now.
Obstet Gynecol
July 2025
Ana I. Tergas is from the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Health, Rutgers New Jersey Medical School, Newark, New Jersey. Mark H. Einstein is from the Department of Obstetrics, Gynecology, and Women's Health, Albert Einstein College of Medicine